Simpson Thacher is representing CSL Limited (ASX: CSL) in connection with its all-cash public tender offer to acquire all publicly held shares of Vifor Pharma Ltd (SIX: VIFN), for US$179.25 per share, for an aggregate equity value for Vifor Pharma of US$11.7 billion. The transaction is subject to various customary closing conditions.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange.
CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Today, CSL–including its two businesses, CSL Behring and Seqirus–provides life-saving products to more than 100 countries and employs more than 25,000 people.
The Simpson Thacher team includes Mark Pflug and Carina Kan (M&A); Brian Steinhardt, Antti Pesonen, Michael Vernace, Jule Walsh and Kyle Nelson (Banking and Credit); Richard Fenyes and Debbie Harris (Capital Markets); Buzz Frahn, Lori Lesser, Raul Duran, Bobbie Burrows and Kate Mirino (IP); Sara Razi, Étienne Renaudeau, Nick Ingros and Pauline Patat (Antitrust); Brian Robbins, Patricia Adams and Ryan Kenny (Executive Compensation and Employee Benefits); Vanessa Burrows and Tera Rule (Healthcare); and Benjamin Rippeon and Lina Pan (Tax).